EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

LC-MS/MS Method Development and Validation for Clinical Pharmacokinetics and Therapeutic Drug Monitoring of Potassium-Competitive Acid Blocker Vonoprazan-Based Triple Therapy for H. pylori in Human Plasma

Naser F Al-Tannak iD, Hani M Hafez iD, Ahmed Hemdan iD, Abdullah Aldasem iD, Ibrahim Khadra iD

Pharmaceuticals · 08.10.2025 · 18 (10) · 1509

DOI: 10.3390/ph18101509 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceuticals, online erschienen am 08.10.2025. Verfasst von Naser F Al-Tannak und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Kuwait University, Kuwait City P.O. Box 46300, Kuwait. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Research Sector- Kuwait University, Research Sector-Kuwait University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

A novel triple therapy regimen for Helicobacter pylori eradication, recently approved by the U.S. FDA, comprises vonoprazan (VPN), a potassium-competitive acid blocker, in combination with amoxicillin (AMX) and clarithromycin (CMN). This study presents the development and full validation of a rapid, selective, and sensitive LC-MS/MS method for the simultaneous quantification of these three drugs in spiked human plasma.

Methods

Sample preparation was performed using a simple and efficient liquid–liquid extraction (LLE) technique. Chromatographic separation was achieved within 5 min using a Phenomenex Kinetex C18 column (100 × 4.6 mm, 2.6 µm) and a gradient elution system consisting of 0.1% formic acid in water and acetonitrile. Moreover, diazepam was used as an internal standard. The mass spectrometric detection was conducted in multiple reaction monitoring (MRM) mode using positive electrospray ionization.

Results

The method exhibited excellent linearity over the investigated concentration ranges (2, 5, 10, 20, 50, and 100 ng/mL for amoxicillin and clarithromycin and 5, 10, 20, 30, 50, and 100 ng/mL for vonoprazan). Intra- and inter-day precision and accuracy values met FDA bioanalytical method validation guidelines, with relative standard deviations and relative errors below 15%. Mean absolute recoveries were above 93% for all analytes.

Conclusions

The developed method was fully validated, rapid, selective, and sensitive LC-MS/MS and was assessed using the AGREE tool as a greenness assessment approach, confirming its environmental friendliness and alignment with green analytical chemistry principles.

Schlagwörter

Stichwörter der Autor:innen

H. pylori infectionLC-MS/MSamoxicillinclarithromycingreen chemistryvonoprazan

Autor:innen und Institutionen

  • Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Kuwait University, Kuwait City P.O. Box 46300, Kuwait.
  • Pharmacy College, Al-Esraa University, Baghdad 10069, Iraq.
  • Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, 161, Cathedral Street, Glasgow G4 0RE 1, UK.

ORCID-Profile: Naser F Al-Tannak, Hani M Hafez, Ahmed Hemdan, Abdullah Aldasem, Ibrahim Khadra

Förderung

  • Research Sector- Kuwait University
  • Research Sector-Kuwait University

Zitieren

APA

Al-Tannak, N. F., Hafez, H. M., Hemdan, A., Aldasem, A., & Khadra, I. (2025). LC-MS/MS Method Development and Validation for Clinical Pharmacokinetics and Therapeutic Drug Monitoring of Potassium-Competitive Acid Blocker Vonoprazan-Based Triple Therapy for H. pylori in Human Plasma. Pharmaceuticals, 18(10), 1509. https://doi.org/10.3390/ph18101509

Vancouver

Al-Tannak NF, Hafez HM, Hemdan A, Aldasem A, Khadra I. LC-MS/MS Method Development and Validation for Clinical Pharmacokinetics and Therapeutic Drug Monitoring of Potassium-Competitive Acid Blocker Vonoprazan-Based Triple Therapy for H. pylori in Human Plasma. Pharmaceuticals. 2025;18(10):1509. doi:10.3390/ph18101509

BibTeX
@article{AlTannak2025,
  author = {Al-Tannak, Naser F and Hafez, Hani M and Hemdan, Ahmed and Aldasem, Abdullah and Khadra, Ibrahim},
  title = {LC-MS/MS Method Development and Validation for Clinical Pharmacokinetics and Therapeutic Drug Monitoring of Potassium-Competitive Acid Blocker Vonoprazan-Based Triple Therapy for H. pylori in Human Plasma},
  journal = {Pharmaceuticals},
  year = {2025},
  volume = {18},
  number = {10},
  pages = {1509},
  doi = {10.3390/ph18101509}
}
Kostenlos starten →